Leigh syndrome affects roughly 1 in 40,000 people, making it the most common pediatric mitochondrial disease. That still places it firmly in the rare disease category, but certain populations carry the condition at dramatically higher rates due to inherited founder mutations.
Overall Prevalence
Across the general population, Leigh syndrome occurs in approximately 1 in 40,000 live births, with no significant difference between males and females. Registry data shows an almost even split, with 47% female and 47% male participants (the remainder not reporting biological sex). The condition appears across all ethnic groups and geographic regions, though the vast majority of documented cases in large registries have involved white patients, likely reflecting disparities in access to genetic testing and specialty care rather than true differences in biology.
Because Leigh syndrome can be caused by mutations in a large number of different genes, both in mitochondrial DNA and nuclear DNA, the overall incidence captures a genetically diverse group of patients who share a common pattern of brain damage but may have arrived there through very different molecular pathways.
Populations With Much Higher Rates
In a few geographically isolated communities, specific genetic mutations have accumulated over generations, pushing Leigh syndrome rates far above the global average. The most striking example is the Saguenay-Lac-Saint-Jean region of Quebec, Canada, where a founder mutation in the LRPPRC gene has a carrier frequency of 1 in 23. That translates to roughly 1 in 2,000 births affected, a rate 20 times higher than the worldwide average.
A similar founder effect exists in the Faroe Islands, a small archipelago between Norway and Iceland. There, a mutation in the SUCLA2 gene traces back to a common ancestor, producing an estimated homozygote frequency of about 1 in 2,500. The British Pakistani population also carries a notably prevalent LRPPRC variant. And in Saudi Arabia, mutations affecting a thiamine transporter gene occur at unusually high frequency, causing a spectrum of disease that includes Leigh syndrome.
These clusters illustrate a broader principle: rare diseases can become locally common when small, isolated populations share ancestry. If you have family roots in one of these regions, carrier testing may be relevant even without a family history of the condition.
When Symptoms Typically Appear
Leigh syndrome usually becomes apparent in the first year of life. Early signs often look deceptively ordinary: vomiting, diarrhea, and difficulty swallowing that interfere with feeding. As the disease progresses, more distinctive neurological problems emerge, including weak muscle tone, involuntary muscle contractions, and trouble with balance and coordination. Developmental milestones that a child had already reached may start to slip away.
A small number of people don’t develop symptoms until adulthood, and their disease tends to progress more slowly. In adults, the presentation can mimic Parkinson’s disease, certain types of inherited ataxia, or even multiple sclerosis, which makes diagnosis especially challenging in that group.
How Leigh Syndrome Is Diagnosed
The hallmark finding on brain MRI is a distinctive pattern of symmetric damage in deep brain structures, particularly the basal ganglia and brainstem. These areas show up as bright spots on certain MRI sequences, reflecting spongy, deteriorating tissue. This imaging pattern, combined with elevated lactate levels in the blood or spinal fluid and progressive neurological decline, forms the core diagnostic criteria.
Getting to that diagnosis, however, is often slow. Many families go through rounds of specialist appointments before the pieces come together. Genetic testing can confirm the specific mutation responsible, but results typically take weeks or months to return. In countries with limited access to advanced genetic testing, the diagnostic process can stretch even longer. Some experts recommend running basic metabolic blood and urine tests in parallel with genetic studies, since those results come back quickly and can point clinicians in the right direction while waiting for definitive genetic confirmation.
Prognosis and Survival
Leigh syndrome carries a serious prognosis, particularly when symptoms appear early. In a study of Japanese patients, the median age of death was 31.5 months, with the highest concentration of deaths occurring around 1 year of age. Among those who died, the typical disease course from first symptoms to death lasted about 23.5 months. By age 6, 87.5% of deceased patients had already passed.
The timing of symptom onset matters enormously. Children whose symptoms began before 6 months of age had a mortality rate of 40.3%, compared to 14.3% for those with onset after 6 months. Every patient with neonatal onset (symptoms from birth) was either deceased or completely bedridden at the time of analysis. Certain genetic subtypes also carry higher risk: mutations in MT-ND5 were associated with an 85.7% mortality rate.
Late-onset cases, while still serious, follow a less aggressive course. Adults diagnosed with Leigh syndrome generally experience a slower decline, though the condition remains progressive and life-altering for the majority of those affected.